HOPA Annual Conference 2019

Wednesday, April 3

9–10:30 am

Commercially Supported Symposium (CSS)
Today’s Concepts in EGFR TKIs for NSCLC

Supported by AstraZeneca

Val R. Adams, PharmD, FCCP, BCOP
Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Matthew Gubens, MD MS
Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Philip Schwieterman, PharmD MHA
Director of Oncology and Pediatric Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

The therapeutic landscape for EGFR-mutated advanced or metastatic non-small-cell lung cancer (NSCLC) continues to evolve. With the availability of multiple EGFR TKIs, managed care pharmacy professionals will benefit from practical guidance on how best to integrate these agents into care plans for their patients, especially clinical challenges and questions regarding the optimal sequencing of EGFR TKI therapy.

In this interactive symposium, oncology and pharmacy expert panelists will provide their perspectives on the latest clinical evidence shaping optimal use of EGFR-targeted therapies in the management of patients with advanced EGFR-mutated NSCLC, including:
•  Importance of molecular testing
•  Comparative efficacy of EGFR TKIs as related to the landscape of EGFR mutations
•  EGFR TKI pharmacology, including comparison of toxicities and CNS activity
•  Insights into the latest first-line and second-line clinical data on available EGFR TKIs
•  A role for immunotherapy in the setting of acquired resistance to EGFR TKIs
•  Implementing clinical pathways in advanced EGFR-mutated NSCLC to deliver quality care

Attendees will have the opportunity to interact with the expert panelists during open discussion built into the agenda and will have the ability to text in questions and case challenges to the program faculty throughout the event.


10:45–11:45 am

Non-CE Symposium
Immuno-oncology Research: Translating Cellular Pathways Into Clinical Practice

Supported by Bristol Meyers Squibb

Benjamin Thompson, PharmD BCOP
Immuno-Oncology Clinical Liaison
US Oncology Field Medical | Bristol-Myers Squibb


7–7:45 pm

Corporate Showcase
XOSPATA® (gilteritinib): A Targeted Therapeutic Approach for Relapsed or Refractory FLT3m+ AML Patients

Supported by Astellas

Jeff Klaus, PharmD


7–7:45 pm

Corporate Showcase
Clinical Review of CABOMETYX®: Approved Treatment Option for Both HCC and Advanced RCC

Supported by Exelixis

Jessica Davis, PharmD

Thursday, April 4

7–8:00 am

Non-CE Symposium
Management of CLL, AML and the Role of the BCL-2 Pathway Inhibition

Supported by Abbvie

Dan Wojenski, PharmD BCPS BCOP


7–8:00 am

Non-CE Symposium
Frontline Treatment of CD30-Expressing Lymphomas

Supported by Seattle Genetics

Kirollos Hanna, PharmD BCOP BCPS


Noon–1:00 pm

Non-CE Symposium
Improving Outcomes in Patients With Newly Diagnosed secondary AML

Supported by Jazz

Katie Culos, PharmD BCOP


Noon–1:00 pm

Non-CE Symposium
Don’t Delay - Recognizing and Treating Patients with Early Onset Severe Toxicity to 5-FU and Capecitabine

Supported by Wellstat Therapeutics

Amber Draper, PharmD BCOP


6:30–7:15 pm

Corporate Showcase
Are You Ready for Biosimilars? What the Oncology Team Should Know

Supported by Amgen

Christopher Campen, PharmD, BCOP


6:30–7:15 pm

Corporate Showcase
A Treatment Option for Patients With HR+, HER2- Advanced or Metastatic Breast Cancer

Supported by Lilly

Rodney J. Hunter, PharmD, BCOP

Friday, April 5

7–8:00 am

Commercially Supported Symposium
A New Frontier in Cancer Therapy: Examining the Role of PARP Inhibitors in an Emerging Paradigm

Accredited by Creative Educational Concepts
Supported by Astra Zeneca

Jason Bergsbaken, PharmD BCOP
Pharmacy Coordinator, Regional Oncology Services
UW Health
Madison, Wisconsin

Nadine M. Tung, MD
Chief, Breast Medical Oncology
Director, Cancer Genetics and Prevention Program
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Attendees of this symposium will explore the new frontier of PARP inhibition in cancer therapy, including the latest advances in targeting the DDR pathway, as well as current and emerging trial data for PARP inhibitors in breast, ovarian, prostate, and pancreatic cancers. Using case-based strategies, faculty will evaluate clinical challenges and propose innovative methodologies by which oncology pharmacists can manage adverse events, enhance adherence, and optimize outcomes for patients taking PARP inhibitors.


7–8:00 am

Commercially Supported Symposium
Immunotherapy for Genitourinary Cancers: New Options, New Challenges

Accredited by Medscape
Supported by Merck and Exelixis

Steven Ludlow, PharmD BCOP BCPS
H. Lee Moffitt Cancer Centerand Research Institute

Kirollos S. Hanna, PharmD BCPS BCOP
University of Minnesota Medical Center & Mayo Clinic

Pharmacists are integral members of the cancer care team, working together with other healthcare professionals to keep abreast of the latest clinical developments and to apply their knowledge of drug interactions, dosing, and side effects to make optimal patient-specific treatment recommendations. Pharmacists are also involved in patient counseling and are often looked to for managing and mitigating adverse events. As part of an interdisciplinary team, oncology pharmacists can apply their specialized knowledge of anticancer medications to optimize the benefits of drug therapy and provide recommendations for safe implementation of therapeutic care plans. In this exciting, live CE-certified symposium, 2 leading oncology pharmacists will delve into the changing and complicated landscape of genitourinary cancers. The panel will discuss topics critical to keep oncology pharmacists knowledgeable of the clinical trial data with immune checkpoint inhibitors, and how to anticipate, recognize, and manage therapy-related adverse events to achieve desired endpoints in patients with bladder and kidney cancer.


Noon–1:00 pm

Transforming the Treatment Paradigm in B-Cell Malignancies: Pharmacist Insights into BTK Inhibitors

Accredited by Creative Educational Concepts
Supported by AstraZeneca

John Allan, MD
Weill Cornell Medicine

Megan Dillaman, PharmD BCOP
West Virginia University Medicine

Shilpa Paul, PharmD BCOP
University of Texas MD Anderson Cancer Center

This initiative is targeted to pharmacists attending the 2019 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting. Attendees of this symposium will gain insight into the latest clinical and scientific advances in the treatment and management of patients on BTK inhibitors (BTKis), including current safety and efficacy data of BTKi’s in various B-cell malignancies, both in monotherapy and in combination with other anti-neoplastic agents. Attendees will also explore the various mechanisms of resistance found in BTK inhibitors and strategies that can be used to prevent or mitigate its occurrence. Using a case-based approach, discussion on anticipating and managing adverse events, therapy selection, and improving adherence will be incorporated into this cutting-edge symposium.


Noon–1:00 pm

Advancing Technology to Minimize Unintended Exposure to Hazardous Drugs

Accredited by Pharmacy Times
Supported by Sun Pharmaceuticals, Inc.

Marc Earl, PharmD BCOP


Learning Objectives:

  • Characterize the risks of unintentional exposure to chemotherapeutic agents
  • Examine how dose banding and RTA technology may provide clinical and safety benefits
  • Analyze novel technology that is available to prevent unintentional exposure to chemotherapeutic agents


5:30–6:15 pm

Corporate Showcase
Case-Based Review of Consensus Guidelines for Management of Patients with Delayed Methotrexate Clearance and Renal Impairment.

Supported by BTG

Heidi Trinkman, PharmD


5:30–6:15 pm

Corporate Showcase
An Immunotherapy Treatment Option for Patients with Advanced Cutaneous Squamous Cell Carcinoma

Supported by Regeneron

Dr. Michelle Ashworth

Saturday, April 6

7–7:45 am

Corporate Showcase
A Case-Based Program: Transforming the Treatment of NSCLC Options for First-Line Treatment of Metastatic EGFR Mutation-Positive Disease and Immunotherapy for Stage III Unresectable Disease

Supported by AstraZeneca

Martin Dietrich, MD, PhD


12:30–1:30 pm

Non-CE Symposium
An Overview of Rituxan Hycela

Supported by Genentech

Jacob Kettle